OGT launches enhanced genetic profiling panel for CLL

New SureSeq CLL + CNV V3 panel improves understanding of CLL

OGT has announced the launch of its enhanced SureSeq CLL + CNV V3 Panel, which offers more comprehensive genetic profiling for chronic lymphocytic leukaemia (CLL) samples. This new panel includes advanced proprietary bait designs for better gene coverage and improved CNV detection.

Giulia Poloni, SureSeq Product Manager at OGT, said, “Working with leading cancer experts, including from within the ERIC Consortium, we have identified key areas for enhancement and acted upon these to develop a product that meets the demands of busy laboratories today for CLL.”

”The upgraded panel now covers more targeted genes and boasts higher probe density, allowing for better tumour content estimation and reducing inter-run variability by using internal reference DNA. OGT’s analysis software, Interpret, demonstrated a 38% increase in CNV detection with the new panel.

Recent trials have shown the panel’s capability in detecting TP53 SNVs with 100% accuracy, even at low variant allele fractions (VAF).

The panel also showed 99% concordance with FISH testing for CNVs down to 20% tumour content.

Anna Sobczyńska-Konefał from the Lower Silesian Center for Oncology in Poland highlighted the panel’s accessibility and ease of use, noting its integration with bioinformatics software for simplified data analysis. “The CLL + CNV V3 panel is invaluable for our research as it enables us to identify key CLL-associated biomarkers,” she said.

The SureSeq CLL + CNV V3 Panel aims to help researchers make informed decisions about their samples, improving confidence in disease classification and enhancing the understanding of CLL progression.

The panel, coupled with OGT’s Interpret software, maximises efficiency without requiring additional bioinformatic resources.